Literature DB >> 7748011

Controversies in lupus: nervous system involvement.

G A Bruyn1.   

Abstract

What have we learned about CNS lupus in recent years? An enormous amount of knowledge on pathophysiology of antiphospholipid antibodies, in particular, has been gathered. Although hard evidence of a direct pathogenetic role of these antibodies in cerebral lupus is still lacking, it is generally felt that the multiple microinfarctions found in the brains of lupus patients are related to their presence. Better understanding of the pathogenesis of cerebral lupus will come from the study of experimental models, as it has been possible to develop an antiphospholipid antibody syndrome in mice. Because no specific laboratory test for CNS lupus is yet available, diagnosing the condition remains a challenge to every clinician. Techniques including neuropsychometric testing, quantitative EEG, and SPECT scans have taught us more about cognitive dysfunction and psychosis in patients with SLE. These categories remain the most difficult to define. The concept of hypercoagulability in SLE patients has diverted the direction of therapy from immunosuppression towards anticoagulation. It is of utmost importance that randomised trials are commenced in order to determine the optimal mode of anticoagulation for various groups of lupus patients. It will be necessary to conduct such trials under strict inclusion criteria, based on well defined patient categories. Such an enterprise will require international co-operation of investigators.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7748011      PMCID: PMC1005546          DOI: 10.1136/ard.54.3.159

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  86 in total

1.  Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.

Authors:  D Alarcón-Segovia; M Delezé; C V Oria; J Sánchez-Guerrero; L Gómez-Pacheco; J Cabiedes; L Fernández; S Ponce de León
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

2.  Magnetic resonance imaging versus computed tomographic scanning in neuropsychiatric systemic lupus erythematosus.

Authors:  K L Sewell; A Livneh; C B Aranow; A I Grayzel
Journal:  Am J Med       Date:  1989-05       Impact factor: 4.965

3.  Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.

Authors:  N Futrell; C Millikan
Journal:  Stroke       Date:  1989-05       Impact factor: 7.914

4.  A novel neuronal antigen identified by sera from patients with systemic lupus erythematosus.

Authors:  J G Hanly; S Rajaraman; S Behmann; J A Denburg
Journal:  Arthritis Rheum       Date:  1988-12

5.  Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning.

Authors:  W J McCune; A MacGuire; A Aisen; S Gebarski
Journal:  Arthritis Rheum       Date:  1988-02

6.  Antineurofilament antibody evaluation in neuropsychiatric systemic lupus erythematosus. Combination with anticardiolipin antibody assay and magnetic resonance imaging.

Authors:  M L Robbins; S E Kornguth; C L Bell; T Kalinke; D England; P Turski; F M Graziano
Journal:  Arthritis Rheum       Date:  1988-05

7.  Cerebral blood flow variations in CNS lupus.

Authors:  M J Kushner; M Tobin; F Fazekas; J Chawluk; D Jamieson; B Freundlich; S Grenell; L Freemen; M Reivich
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

8.  Amaurosis fugax associated with antiphospholipid antibodies.

Authors:  K B Digre; F J Durcan; D W Branch; D M Jacobson; M W Varner; J R Baringer
Journal:  Ann Neurol       Date:  1989-03       Impact factor: 10.422

9.  Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome.

Authors:  R A Asherson; M A Khamashta; A Gil; J J Vazquez; O Chan; E Baguley; G R Hughes
Journal:  Am J Med       Date:  1989-04       Impact factor: 4.965

10.  Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus.

Authors:  W J McCune; J Golbus; W Zeldes; P Bohlke; R Dunne; D A Fox
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

View more
  18 in total

Review 1.  CNS involvement in primary Sjögren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach.

Authors:  M Govoni; M Padovan; N Rizzo; F Trotta
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Sensitivity of quantitative (1)H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus.

Authors:  J S Axford; F A Howe; C Heron; J R Griffiths
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

3.  Perfusion-weighted MR imaging in cerebral lupus erythematosus.

Authors:  Page I Wang; Patricia C Cagnoli; William J McCune; Tobias Schmidt-Wilcke; Suzan E Lowe; Courtney C Graft; Stephen S Gebarski; Thomas L Chenevert; Shokoufeh Khalatbari; James D Myles; Kuanwong Watcharotone; Paul Cronin; Pia C Sundgren
Journal:  Acad Radiol       Date:  2012-05-17       Impact factor: 3.173

4.  Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET.

Authors:  S M Weiner; A Otte; M Schumacher; R Klein; J Gutfleisch; I Brink; P Otto; E U Nitzsche; E Moser; H H Peter
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

5.  Behavioral heterogeneity in an animal model of neuropsychiatric lupus.

Authors:  Boris Sakic; Steven E Hanna; Jason M Millward
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

6.  Raised serum S100B protein levels in neuropsychiatric lupus.

Authors:  C B Schenatto; R M Xavier; M Bredemeier; L V C Portela; A B L Tort; T L Dedavid e Silva; D O Souza; J C T Brenol
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

7.  Evaluation of the effects of methylprednisolone pulse therapy in patients with systemic lupus erythematosus with brain involvement by Tc-99m HMPAO brain SPECT.

Authors:  S S Sun; W S Huang; J J H Chen; C P Chang; C H Kao; J J Wang
Journal:  Eur Radiol       Date:  2003-12-09       Impact factor: 5.315

8.  Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus.

Authors:  Wilmer L Sibbitt; William M Brooks; Mario Kornfeld; Blaine L Hart; Arthur D Bankhurst; Carlos A Roldan
Journal:  Semin Arthritis Rheum       Date:  2009-10-31       Impact factor: 5.532

9.  Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus erythematosus with brain involvement: a preliminary report.

Authors:  F Y Liu; W S Huang; C H Kao; R F Yen; J J Wang; S T Ho
Journal:  Rheumatol Int       Date:  2003-01-30       Impact factor: 2.631

10.  Hippocampal damage in mouse and human forms of systemic autoimmune disease.

Authors:  David A Ballok; John Woulfe; Monalisa Sur; Michael Cyr; Boris Sakic
Journal:  Hippocampus       Date:  2004       Impact factor: 3.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.